RxDoctor Payments Data

Arpita Patel, MD

Neurology · Cedar Park, TXNPI 1538343769

Payments from drug & device makers

$8,054in general payments, 2019–2025

Across 443 payments — averaging $18.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$1K
  • AbbVie$1K
  • Biogen$574
  • Amgen$507
  • Pfizer$402
  • Lilly USA, LLC$309
  • plus $4K from 40 others

What the payments were for

  • Consulting fees$1502%
  • Food & beverage$7,67295%
  • Education$2323%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,054 in reported general payments places this provider in the 60th percentile of 1,246 neurology providers in Texas.

See all neurology providers in Texas

Medicare billing

Part B allowed, 2024
$105,894
Medicare patients
481
Services billed
1,018

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Kesimpta PenOfatumumab12$103,146
VumerityDiroximel Fumarate12$96,876
Aimovig AutoinjectorErenumab-Aooe35$40,360
Nurtec OdtRimegepant Sulfate33$39,042
QuliptaAtogepant12$28,107
UbrelvyUbrogepant13$20,274
NamzaricMemantine Hcl/Donepezil Hcl16$13,800
Memantine Hcl344$10,022
Lacosamide62$8,191
Donepezil Hcl463$5,619
Gabapentin185$5,267
Carbamazepine75$5,187
Levetiracetam135$4,878
Carbidopa-LevodopaCarbidopa/Levodopa141$3,883
Rivastigmine21$3,847

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BiogenVumerity$574$96,87612 claims
AbbVieQulipta, Ubrelvy, Namzaric$1,126$62,18041 claims
PfizerNurtec Odt$402$39,04233 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$12$1,08911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,246 neurology providers in Texas.

Other neurology in Cedar Park

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →